Abstract
Actinic keratosis (AK) is the most common precancerous skin lesion. AKs present on sun-damaged skin as pink to red gritty macules or papules. Patients with numerous AKs are at increased risk of developing skin cancer. AK development represents the initial step in keratinocytes’ progression to squamous cell carcinoma. Patients with numerous AKs are at increased risk of developing skin cancer. Treatment options for AKs include cryosurgery, topical chemotherapies, chemical peels, and laser surgery. Prevention is of utmost importance, including photoprotection such as sun protective clothing and sunscreens.
Keywords
Actinic keratosis Solar keratosis Photodamage Precancerous Cryosurgery Topical chemotherapy Sun protectionReferences
- 1.Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68(1):S2–9.CrossRefPubMedGoogle Scholar
- 2.James WD, Elston DM, Berger TG, Elston DM. Epidermal nevi, neoplasms, and cysts. In: James WD, Berger TG, Elston DM, editors. Andrews' diseases of the skin. 12th ed. Philadelphia: Elsevier; 2016.Google Scholar
- 3.Chen GJ, Feldman SR, Williford PM, Hester EJ, Kiang S-H, Gill I, et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg. 2005;31(1):43–7.CrossRefPubMedGoogle Scholar
- 4.Dodson JM. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. AMA Dermatol. 1991;127(7):1029–31.CrossRefGoogle Scholar
- 5.Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol. 2007;157(s2):18–20.CrossRefPubMedGoogle Scholar
- 6.Nair PA, Chaudhary AH, Mehta MJ. Actinic keratosis underlying cutaneous horn at an unusual site— a case report. E Cancer Med Sci. 2013;7:376.Google Scholar
- 7.Soyer HP, Rigel DS, Wurm EMT. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. In: Bolognia J, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Philadelphia: Elsevier; 2012.Google Scholar
- 8.Zalaudek I, Ferrara G, Leinweber B, Mercogliano A, D'Ambrosio A, Argenziano G. Pitfalls in the clinical and dermoscopic diagnosis of pigmented actinic keratosis. J Am Acad Dermatol. 2005 Dec;53(6):1071–4.CrossRefPubMedGoogle Scholar
- 9.Bagazgoitia L, Cuevas J, Expression JA. Of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease. J Eur Acad Dermatol Venereol. 2005;24(2):228–30.CrossRefGoogle Scholar
- 10.Rowert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(3):8–12.CrossRefPubMedGoogle Scholar
- 11.Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - international league of dermatological societies in cooperation with the European dermatology forum - short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069–79.CrossRefPubMedGoogle Scholar
- 12.Trost LB, Bailin PL. Cryosurgery. In: Vidimos AT, Ammirati CT, Poblete-Lopez C, editors. Dermatologic surgery. Philadelphia: Elsevier; 2009.Google Scholar
- 13.Kuflik EG, Kuflik JH. Cryosurgery. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Philadelphia: Elsevier; 2012.Google Scholar
- 14.Pomerantz H, Hogan D, Eilers D. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis. JAMA Dermatol. 2015;151(9):952–60.CrossRefPubMedGoogle Scholar
- 15.Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis – a systemic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453–63.CrossRefPubMedGoogle Scholar
- 16.Ritchie SA, Patel MJ, Miller SJ. Therapeutic options to decrease actinic keratosis and squa- mous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg. 2012 May;38(10):1604–21.CrossRefPubMedGoogle Scholar
- 17.Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overview. Int J Dermatol. 2016;55(8):831–44.CrossRefPubMedGoogle Scholar
- 18.Stockfleth E. Lmax and imiquimod 3.75%: the new standard in AK management. J Eur Acad Dermatol Venereol. 2015;29(Supp.1):9–14.CrossRefPubMedGoogle Scholar
- 19.Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratosis in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157(Suppl 2):25–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Jenkins SN, Speck K, Actinic CSC. Keratosis and bowen’s disease. In: Bigby M, Herxheimer A, editors. Evidence based dermatology. 3rd ed. Chichester, England: Wiley-Blackwell; 2014.Google Scholar
- 21.Gold MH. Lasers, photodynamic therapy, and the treatment of medical dermatological conditions. In: Goldberg DJ, editor. Laser dermatology. New York: Springer Publishing; 2005.Google Scholar
- 22.Hantash BM, Stewart DB, Cooper ZA. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006;142(8):976–82.CrossRefPubMedGoogle Scholar
- 23.Iyer SS, Friedli A, Bowes L, Kricorian G. Full face laser resurfacing: therapy and prophylaxis for actinic keratosis and non-melanoma skin cancer. Lasers Surg Med. 2004;34(2):114–9.CrossRefPubMedGoogle Scholar
- 24.Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, Department of Veterans Affairs Topical Tretinoin Chemoprevention Trial Group. Natural history and risk of malignant transformation in the veterans affairs topical Tretinoin chemoprevention trial. Cancer. 2009;115(11):2523–30.CrossRefPubMedGoogle Scholar
- 25.Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16(4):335–9.PubMedGoogle Scholar
- 26.Madigan LM, Lim HW. Tanning beds: impact on health, and recent regulations. Clin Dermatol. 2016;34(5):640–8.CrossRefPubMedGoogle Scholar
- 27.Nikolaou V, Stratigos AJ, Tsao H. Hereditary nonmelanoma skin cancer. Semin Cutan Med Surg. 2012;31(4):204–10.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol. 1995;131(2):170–5.CrossRefPubMedGoogle Scholar
- 29.Darlington S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol. 2003;139(4):451–5.CrossRefPubMedGoogle Scholar
- 30.Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329(16):1147–51.CrossRefPubMedGoogle Scholar
Copyright information
© Springer International Publishing AG, part of Springer Nature 2018